| Name | Mitotic spindle assembly checkpoint protein MAD2A | ||
| UniProt ID | MD2L1_HUMAN | ||
| Gene Name | MAD2L1 | ||
| Gene ID | 4085 | ||
| Synonyms |
MAD2L1, HSMAD2, MAD2
|
||
| Sequence |
MALQLSREQGITLRGSAEIVAEFFSFGINSILYQRGIYPSETFTRVQKYGLTLLVTTDLE
LIKYLNNVVEQLKDWLYKCSVQKLVVVISNIESGEVLERWQFDIECDKTAKDDSAPREKS QKAIQDEIRSVIRQITATVTFLPLLEVSCSFDLLIYTDKDLVVPEKWEESGPQFITNSEE VRLRSFTTTIHKVNSMVAYKIPVND |
||
| Pathway Map | MAP LINK | ||
| KEGG ID | hsa4085 | ||
| Pfam | PF02301; PF10033; PF18173 | ||
| Pair Name | Dihydrotanshinone I, Cisplatin | |||
| Phytochemical | Dihydrotanshinone I | |||
| Drug | Cisplatin | |||
| Disease Info | [ICD-11: 2D10.Z] | Thyroid cancer | Investigative | |
| Regulate Info | Down-regulation | Mitotic spindle assembly checkpoint protein MAD2A | Expression | |
| Result | The present study is the first to demonstrate that DHT exerts antitumor effects on ATC cells by reducing MAD2 expression levels. Moreover, a synergistic effect of DHT with cisplatin was shown. Further in vivo studies are required to assess this phytochemical compound as a potential adjuvant for the treatment of ATC. | |||
